Since announcing our $25 million Series B last week, the support for Lumonus’ future has been incredibly encouraging. But beyond the financial milestone, I want to talk about why this moment feels so significant and what it means for everyone fighting cancer.
Why it matters
I’ve had the privilege of serving in healthcare leadership for the past 15 years. During this time, I’ve witnessed extraordinary breakthroughs in cancer care — precision medicine, immunotherapy, radiopharmaceuticals, targeted agents, and therapeutic technologies that were once unimaginable are now part of routine clinical practice.
Yet, while the science has leapt forward, the systems that support care teams have lagged far behind. A telling example: healthcare still leans heavily on fax machines, a relic most other industries abandoned decades ago. This gap between clinical innovation and workflow innovation has created mounting challenges; escalating clinical complexity, high administrative burdens, and unsustainable rates of clinician burnout.
At Lumonus, our purpose is simple but ambitious: empower care teams to transform care. We’re building AI-native solutions designed specifically for oncology, combining an end-to-end workflow approach with a deep commitment to solving real-world pain points alongside care teams. By reimagining oncology workflows, we aim to give clinicians back time, reduce administrative burden, and allow innovation in workflow to match the innovation in clinical care.
The impact so far
When I look back at the impact Lumonus has made in the real world I feel proud. Over 280,000 prescriptions by our platform. More than 75,000 treatment plans have been generated automatically. But here's what those numbers really mean:
- Physicians spending 40% less time on administrative tasks
- Treatment planning costs improving by 30%+
- Patients commencing treatment up to 2 weeks earlier
The human element behind the technology
What sets us apart isn’t just technology — it’s people. This milestone reflects the dedication of our team, who work side by side with clinicians worldwide to deliver real impact today and help shape the future of cancer care.
Our team includes radiation oncologists, physicists, dosimetrists, engineers, product leaders, and an experienced executive team — together bringing more than 100 years of combined clinical, operational and technical expertise across the US, Europe, and APAC. This deep grounding in oncology practice ensures we design solutions that solve real problems. When health systems like US Oncology and GenesisCare partner with us, they’re not just buying software—they’re partnering with people who understand their challenges and share their mission.
The ripple effect we're creating
This funding round represents far more than capital — it signals that healthcare is ready for transformational change, not just incremental steps forward. Around the world, health systems are recognizing AI as a breakthrough technology with the power to amplify their most valuable resource: the dedicated professionals who devote their lives to caring for patients. The momentum is already clear, with investment and adoption of AI in healthcare accelerating at unprecedented speed.
The path forward
Looking ahead, I see three critical areas where we'll concentrate our efforts:
- Scaling our teams and market reach: Expanding our go-to-market and clinical success teams to support more providers ready to transform their workflows. This means deeper partnerships, faster implementations, and ensuring every customer achieves measurable impact.
- Advancing our core platforms: Continuing to enhance Lumonus AI Physician and Lumonus AI Dosimetry while investing in clinical informatics capabilities that help providers harness real-world evidence and measure quality improvements.
- Delivering data-driven outcomes: Working closely with providers to improve operational performance and deliver increasingly personalized, evidence-based care through better data insights and workflow optimization.
A personal commitment
This Series B represents an opportunity to accelerate the work we’ve started, giving us the resources to move faster, go deeper and expand the impact we’re already delivering alongside care teams.
To our customers: thank you for trusting us with your workflows and your patients. Innovation in healthcare doesn’t happen in isolation — it requires partners who are willing to challenge the status quo, embrace new ways of working, and co-create the future with us. Your readiness to innovate is what makes our work possible. You are the reason we exist, the reason we get up every day, and the driving force behind our purpose to empower care teams to transform cancer care.
To our investors: thank you for believing in us as a team and investing in the opportunity for technology to amplify human expertise and transform cancer care.
To our team: let’s continue building something extraordinary.
The future of cancer care will not be defined by one single breakthrough. It will emerge from thousands of improvements, multiplied across millions of patient interactions — powered by technology that respects both the complexity and humanity of oncology.
The breakthroughs of tomorrow will come from the actions we take today
-
